Simulect 20mg Injection

Simulect 20 mg Injection contains basiliximab, a monoclonal antibody used as an immunosuppressive agent in organ transplantation. It is primarily administered to help prevent acute organ rejection following kidney transplantation.

This medicine is used in combination with other immunosuppressive therapies and is administered under strict medical supervision in hospital settings.

Indications

Simulect 20 mg is indicated for:

• Prevention of acute rejection in patients receiving a kidney transplant

• Use in both adult and pediatric transplant recipients

• Part of combination immunosuppressive regimens including ciclosporin and corticosteroids

How It Works

Basiliximab is a chimeric monoclonal antibody that binds specifically to the interleukin-2 (IL-2) receptor alpha-chain CD25 on activated T-lymphocytes.

By blocking IL-2 mediated activation of lymphocytes, it reduces the immune response responsible for organ rejection.

Usual Dosing (Hospital Protocol Based)

• Adults: Two doses of 20 mg

  • First dose within 2 hours prior to transplantation

  • Second dose on Day 4 after transplantation

Dosing may vary depending on institutional protocol and patient condition. Administration must be supervised by transplant specialists.

Possible Side Effects

Commonly reported side effects may include:

• Gastrointestinal symptoms

• Increased risk of infections

• Fever

• Hypertension

• Headache

Patients are monitored closely in transplant centers to manage potential complications.

Storage

• Store in a refrigerator at 2°C to 8°C

• Do not freeze

• Protect from light

• The reconstituted solution should be used as directed by hospital protocol

Important Information

• For hospital use only

• Requires prescription and specialist supervision

• Not intended for self-administration

• Must be used as part of a complete immunosuppressive regimen